Silverback Therapeutics
Seattle
About Silverback Therapeutics
Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways. They developing a new generation of systemically delivered, locally active therapies that potently modulate fundamental disease pathways once deemed inaccessible. Silverback Therapeutics is building a platform technology capable of unlocking potent immuno-modulatory pathways using an established antibody-guided approach for targeting disease sites. The company's proprietary ImmunoTAC technology and integrated R&D approach enables the design of product candidates that can be administered systemically, but that act only at the sites of disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $221.0M
- Funding stage: M&A
- Last round: Series C (Sep 2020)
- Ticker: nasdaq:SBTX
- Website: silverbacktx.com
- Phone: +1 206 456-2900
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/silverback-therapeutics-10933 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.